1 recruiting. .
Follow Reduced-dose Apixaban: new trials by email Literature Review of Reduced-dose Apixaban trials Research Report on Reduced-dose Apixaban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC - Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation | Recruiting | National Medical Research Center for Therapy and Preventive Medicine | 464 | 2026-04-01 | 2026-05-08 |
Atrial Fibrillation (1) · Hemorrhage (1) · Thromboembolism (1)
Arrhythmias, Cardiac (1) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Heart Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Vascular Diseases (1)
BID protein, human (1) · Left Atrial Appendage Closure (1) · N(4)-oleylcytosine arabinoside (1) · apixaban (1)
National Medical Research Center for Therapy and Preventive Medicine (1)
Russia (1)